There was little evidence on people presenting beyond 6 hours or those with a systolic blood pressure over 220 mmHg. However, the committee agreed that some guidance is needed on treating hypertension in these groups and that it is appropriate to extrapolate from the available data to these groups, but that healthcare professionals should take into account the individual risk of harm when considering rapid blood pressure lowering using clinical judgement on a case-by-case basis. 2022 The committee agreed that the evidence to support maintaining the target blood pressure for at least 7 days is weak. They were also concerned about the potential impact on patient flow, bed management and resources in the NHS, so removed the timeframe. The committee discussed the uncertainty about how long to continue acute treatment. However, this evidence review is primarily concerned with treatment within the first 24 hours. The committee highlighted that blood pressure should still remain lowered after acute treatment in order to reduce the longer-term effect of the acute intracerebral haemorrhage. The committee agreed that people receiving intensive blood pressure treatment would not need to stay in hospital for acute management for 7 days. This can be managed through secondary prevention, which can be indicated when treatment is changed from intravenous to an oral route of administration. The committee also noted that longer-term management of blood pressure can be managed in primary care. The committee did not change the existing practice of not offering rapid blood pressure lowering to specific groups that were excluded from the key clinical trial. This is because there is no evidence of whether this would be safe or beneficial. The committee discussed rapid blood pressure lowering for young people aged 16 and 17. 